SCHEMBL5365871

SCHEMBL5365871

COc1cc(O)ccc1C=C1C(=O)Nc2ccc(Br)c(C)c21

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.49
MDM2 Q00987 4/20 0.45
RET P07949 1/20 0.44
PLK4 O00444 2/20 0.42
PLK1 P53350 1/20 0.42
NPC1 O15118 1/20 0.41
LRRK2 Q5S007 1/20 0.41
CHEK1 O14757 1/20 0.41
CES2 O00748 1/20 0.41
PDPK1 O15530 4/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
KDR P35968 1/20 0.38
DHFR P00374 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368885 0.86 KDM4E (0.47) PTPN1MDM2RETPLK4PLK1
SCHEMBL5358811 0.85 MDM2 (0.46) MDM2RETPLK4NPC1LRRK2
SCHEMBL7140043 0.84 PTPN1 (0.49) PTPN1MDM2RETPLK4PLK1
SCHEMBL5361625 0.84 MDM2 (0.53) MDM2RETLRRK2PDPK1
SCHEMBL7138246 0.84 MDM2 (0.42) MDM2PLK4PLK1LRRK2PDPK1
SCHEMBL7139982 0.84 NPC1 (0.60) MDM2PLK4NPC1
SCHEMBL5376996 0.82 MEN1 (0.51) MDM2PLK4PLK1NPC1LRRK2
SCHEMBL5366021 0.82 KDM1A (0.53) MDM2PLK4NPC1
SCHEMBL5373328 0.81 LRRK2 (0.52) MDM2RETPLK4PLK1LRRK2
SCHEMBL5357671 0.80 LRRK2 (0.51) MDM2RETLRRK2PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PTPN1 882/4885MDM2 888/4885RET 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.